Detalles de la búsqueda
1.
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(12): 1423-1433, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37944541
2.
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
J Clin Oncol
; 41(21): 3689-3699, 2023 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37279408
3.
Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.
NEJM Evid
; 1(7): EVIDoa2200006, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38319255
4.
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Leuk Lymphoma
; 61(13): 3188-3197, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32762271
5.
Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up.
Hemasphere
; 6(5): e712, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35441128
Resultados
1 -
5
de 5
1
Próxima >
>>